This phase III trial studies how well a swallowable sponge cell sampling device works in screening patients with esophageal cancer undergoing esophagogastroduodenoscopy. The swallowable sponge cell sampling might be a less-invasive method to collect enough material to allow for early detection of malignancy and guide surveillance endoscopy.
Additional locations may be listed on ClinicalTrials.gov for NCT04214119.
Locations matching your search criteria
United States
Maryland
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer CenterStatus: Active
Contact: stephen meltzer
Phone: 410-502-6057
PRIMARY OBJECTIVES:
I. To perform phase III testing of the combined sponge‐methylation biomarker strategy in vivo in prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE)‐compliant, prospective live cohorts of patients with esophageal adenocarcinoma (EAC)/high grade dysplasia (HGD) and esophageal squamous cell carcinoma (ESCC) and controls.
OUTLINE:
Patients receive swallowable sponge cell sampling device orally (PO) before standard of care esophagogastroduodenoscopy.
After completion of study, patients are followed up for up to 5 years.
Lead OrganizationJohns Hopkins University/Sidney Kimmel Cancer Center
Principal Investigatorstephen meltzer
